Wegovy 7.2mg is a new, higher dose of Wegovy coming soon. But what does it do, when will it launch, and how can you access it? Our clinicians break it all down so you’re informed and ready when it becomes available. 

What is Wegovy 7.2mg 

Wegovy 7.2mg is a new higher dose of the weight loss injection medication currently being developed by Novo Nordisk, the manufacturer of Wegovy.

It contains the same active ingredient (semaglutide) at a higher dose than currently available.  

Like the lower Wegovy doses, it’s a GLP-1 medication. GLP-1s work by mimicking a hormone that helps regulate your blood sugar and suppress your appetite.

It’s designed for people who’ve already seen successful weight loss at the lower-strength doses, to support them in continuing and maintaining that weight loss in the long term. 

Wegovy 7.2mg is presently in development and is pending approval for weight loss treatment. 

Is 7.2mg of Wegovy approved for weight loss?  

Due to the fact it’s still in the approval process, Wegovy 7.2mg hasn’t yet been approved for sale anywhere. 

The manufacturer, Novo Nordisk, submitted their application to the European Medicines Agency (EMA) in July 2025. The approval process typically takes several months. 

When will Wegovy 7.2mg be available in Ireland?

In Ireland, medicines are reviewed and authorised by the Health Products Regulatory Authority (HPRA), which usually comes after EMA approval. Once authorised by the HPRA, it could be made available through private providers within 1–2 months. But authorisation could also take some time. It will hopefully be available between 2026 and 2027. 

Private providers like myBMI are typically able to offer medications 1-2 months after MHRA approval, so Wegovy 7.2mg could be available by mid 2026.

How effective is Wegovy 7.2mg?

Study data show Wegovy 7.2mg to be highly effective for weight loss.  

In a trial of 1,407 adults, those on Wegovy 7.2mg lost 20.7% of their starting weight, after 72 weeks of treatment.  

By comparison those on the 2.4mg semaglutide dose lost 17.5% of their starting weight over 72 weeks.

Those on the 7.2mg dose also experienced fewer side effects than those on the 2.4mg dose. 

How much weight can you lose? 

How much weight you’ll be able to lose on Wegovy will depend on your starting weight. 

In trials, participants lost up to 20.7% of their starting weight over 72 weeks. 

So, if you weigh 100kg, you could potentially lose up to 20.7kg in this time. 

It’s important to note that Wegovy isn’t a miracle drug and shouldn’t be considered a substitute for a healthy lifestyle.  

How much weight you’re able to lose will depend on factors like: 

• your starting weight 

• your age 

• your Wegovy diet 

• you physical activity level 

• genetics 

• hormones 

Wegovy 7.2mg vs Mounjaro  

Current data show that Wegovy 7.2mg can help you lose a similar amount of weight when compared to Mounjaro.

In clinical trials, people on Wegovy 7.2mg lost up to 20.7% of their starting weight.  

In a similar trial, people taking tirzepatide (Mounjaro) lost 20.2% of their starting weight on average. 

Which medication works better for you is ultimately down to your personal preferences. Some people find that Mounjaro works better for them and they tolerate its side effects better, some people find Wegovy easier to tolerate.  

Whichever option you decide to go with, we’re here to support and guide you every step of the way to make your weight loss journey as smooth and manageable as possible. 

Both Wegovy and Mounjaro share some common side effects like: 

• headache 

• nausea 

• vomiting 

• diarrhoea 

• constipation 

• fatigue 

• stomach pain 

Some very common Wegovy side effects that aren’t very common for Mounjaro are fatigue and headaches. 

Some common side effects of Mounjaro that are not common with Wegovy include: 

• skin reactions like eczema, itching, and rashes 

• low blood pressure 

• raised enzyme levels in the pancreas 

• increased levels of calcitonin — a hormone produced by the thyroid that regulates calcium levels 

Sources: 

• Accessing Wegovy for weight loss: Everything you need to know. (2023). Department of Health & Social Care. (Accessed 1 October 2025) 
• Efficacy and Safety of Semaglutide 7.2 mg in Obesity and Type 2 Diabetes: The STEP UP T2D Trial. (2025). Novo Nordisk. (Accessed 1 October 2025) 
• Obesity – Treatment. NHS. (Accessed 1 October 2025) 
• Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence (2025) Novo Nordisk (Accessed 1 October 2025) 
• Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. (2025). The Lancet. (Accessed 1 October 2025) 
• Tirzepatide as Compared with Semaglutide for the Treatment of Obesity | New England Journal of Medicine (2025) (Accessed 1 October 2025) 
• Tirzepatide Once Weekly for the Treatment of Obesity. (2022). The New England Journal of Medicine. (Accessed 1 October 2025)